TY - JOUR
T1 - Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma
AU - Lin, Weitao
AU - Yip, Yim Ling
AU - Jia, Lin
AU - Deng, Wen
AU - Zheng, Hong
AU - Dai, Wei
AU - Ko, Josephine Mun Yee
AU - Lo, Kwok Wai
AU - Chung, Grace Tin Yun
AU - Yip, Kevin Y.
AU - Lee, Sau-Dan
AU - Kwan, Johnny Sheung-Him
AU - Zhang, Jun
AU - Liu, Tengfei
AU - Chan, Jimmy Yu-Wai
AU - Kwong, Dora Lai-Wan
AU - Lee, Victor Ho-Fun
AU - Nicholls, John Malcolm
AU - Busson, Pierre
AU - Liu, Xuefeng
AU - Chiang, Alan Kwok Shing
AU - Hui, Kwai Fung
AU - Kwok, Hin
AU - Cheung, Siu Tim
AU - Cheung, Yuk Chun
AU - Chan, Chi Keung
AU - Li, Bin
AU - Cheung, Annie Lai-Man
AU - Hau, Pok Man
AU - Zhou, Yuan
AU - Tsang, Chi Man
AU - Middeldorp, Jaap
AU - Chen, Honglin
AU - Lung, Maria Li
AU - Tsao, Sai Wah
PY - 2018
Y1 - 2018
N2 - The lack of representative nasopharyngeal carcinoma (NPC) models has seriously hampered research on EBV carcinogenesis and preclinical studies in NPC. Here we report the successful growth of five NPC patient-derived xenografts (PDXs) from fifty-eight attempts of transplantation of NPC specimens into NOD/SCID mice. The take rates for primary and recurrent NPC are 4.9% and 17.6%, respectively. Successful establishment of a new EBV-positive NPC cell line, NPC43, is achieved directly from patient NPC tissues by including Rho-associated coiled-coil containing kinases inhibitor (Y-27632) in culture medium. Spontaneous lytic reactivation of EBV can be observed in NPC43 upon withdrawal of Y-27632. Whole-exome sequencing (WES) reveals a close similarity in mutational profiles of these NPC PDXs with their corresponding patient NPC. Whole-genome sequencing (WGS) further delineates the genomic landscape and sequences of EBV genomes in these newly established NPC models, which supports their potential use in future studies of NPC.
AB - The lack of representative nasopharyngeal carcinoma (NPC) models has seriously hampered research on EBV carcinogenesis and preclinical studies in NPC. Here we report the successful growth of five NPC patient-derived xenografts (PDXs) from fifty-eight attempts of transplantation of NPC specimens into NOD/SCID mice. The take rates for primary and recurrent NPC are 4.9% and 17.6%, respectively. Successful establishment of a new EBV-positive NPC cell line, NPC43, is achieved directly from patient NPC tissues by including Rho-associated coiled-coil containing kinases inhibitor (Y-27632) in culture medium. Spontaneous lytic reactivation of EBV can be observed in NPC43 upon withdrawal of Y-27632. Whole-exome sequencing (WES) reveals a close similarity in mutational profiles of these NPC PDXs with their corresponding patient NPC. Whole-genome sequencing (WGS) further delineates the genomic landscape and sequences of EBV genomes in these newly established NPC models, which supports their potential use in future studies of NPC.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056133082&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30405107
U2 - https://doi.org/10.1038/s41467-018-06889-5
DO - https://doi.org/10.1038/s41467-018-06889-5
M3 - Article
C2 - 30405107
SN - 2041-1723
VL - 9
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 4663
ER -